WHO Issues Report on Antibacterial Development Progress
WHO Releases Latest Report on Antibacterial Development The World Health Organization (WHO) has published its most recent assessment of antibacterial agents, encompassing antibiotics in various stages of clinical and preclinical…
Zimbabwe Achieves WHO Maturity Level 3 in Medicine Regulation, Joining Africa’s Elite Six
Zimbabwe has reached maturity level 3 (ML 3) in the WHO’s classification of regulatory authorities for medicines, marking a significant achievement in healthcare infrastructure. This classification, assessed using WHO’s Global…
Takeda to Secure Global License for Olverembatinib from Ascentage Pharma
Today, Takeda has announced a significant step forward in its oncology portfolio with the signing of an option agreement with Ascentage Pharma. This agreement paves the way for Takeda to…
Vertex Reveals Positive Long-Term CASGEVY™ Data at 2024 EHA Congress
Today, Vertex announced longer-term data for CASGEVY™ (exagamglogene autotemcel [exa-cel]) from global clinical trials involving individuals with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, presented…
FDA Approves Augtyro™ for NTRK-Positive Advanced Solid Tumors
The U.S. Food and Drug Administration (FDA) has granted accelerated approval for Augtyro™ (repotrectinib) for treating adult and pediatric patients (12 years and older) with solid tumors that have a…
FDA Approves BLINCYTO® for CD19-Positive B-ALL Consolidation Phase
Today, the U.S. Food and Drug Administration (FDA) approved BLINCYTO® (blinatumomab) for treating adult and pediatric patients (one month or older) with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia…
ELREXFIO™ Achieves Median Overall Survival Exceeding Two Years in Relapsed or Refractory Multiple Myeloma Patients
Today, detailed overall survival (OS) results from the Phase 2 MagnetisMM-3 study of ELREXFIO™ (elranatamab-bcmm) in heavily pretreated patients with relapsed or refractory multiple myeloma (RRMM) were announced. The study…
Farxiga Gains FDA Approval for Treating Pediatric Type-2 Diabetes in the US
AstraZeneca’s Farxiga (dapagliflozin) has received approval from the US Food and Drug Administration (FDA) to enhance glycemic control in pediatric patients with type-2 diabetes (T2D) aged 10 years and older.…
Scientific Debate on Defeating Aging Concludes with $10,000 Prize and Surprising Verdict, Promising New Investment Opportunities
A pivotal debate titled “How to Defeat Aging,” hosted by Open Longevity at the Foresight Institute on May 27, 2024, concluded with an unexpected outcome that shed light on the…
Enhancing Clinical Trial Productivity Through AI: Insights from eClinical Solutions at Citeline Roundtable, DIA, and Beyond
eClinical Solutions, a global leader in digital clinical software and services, has announced its participation in several upcoming industry events aimed at advancing biopharma efficiency through its elluminate® platform and…
CMI Media Group Utilizes KERV Interactive Technology for Introducing ‘Video Attention’ Metrics in Pharmaceutical Advertising
CMI Media Group, a global healthcare media strategy agency and part of WPP (NYSE: WPP), has announced a pioneering partnership with KERV Interactive, a leader in AI-powered video analysis, performance,…
Bay Area Research Logistics Opens New US Location to Enhance Global Presence and Customer Service
Bay Area Research Logistics (BARL), a prominent provider of clinical trial services, has announced its expansion into the US market with the establishment of a new facility in New York…